Lancet Neurology

Papers
(The H4-Index of Lancet Neurology is 83. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
The East Asian Parkinson Disease Genomics Consortium4795
Implications of the KIWE trial for low-income and lower-middle-income countries732
Multidisciplinary care for amyotrophic lateral sclerosis718
Dementia diagnosis in the anti-amyloid era714
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease654
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply518
Correction to Lancet Neurol 2024; 23: 168–77490
Correction to Lancet Neurol 2022; 21: 42–52445
Correction to Lancet Neurol 2021; 20: 448–59421
Lessons and future directions for GBA1-targeting therapies409
The predictive value and clinical use of the neurological pupillary index – Authors' reply402
Pseudomedicine for sports concussions in the USA381
RAB32 mutation in Parkinson's disease380
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, r329
Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study327
Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study316
Traumatic brain injury research: homogenising heterogeneity310
New therapies for Pompe disease: are we closer to a cure?301
Increasing diversity in dementia research301
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study293
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial281
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial261
Global burden of stroke: dynamic estimates to inform action252
Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study232
A biological classification of Huntington's disease: the Integrated Staging System215
The relevance of social and commercial determinants for neurological health212
Management of atherosclerotic extracranial carotid artery stenosis209
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study199
Anti-CD19 CAR T cells for refractory myasthenia gravis196
A chilly tale of dementia196
Trials in intracerebral haemorrhage: a path to success?186
A study in healing the wounds of trauma183
Epilepsy syndromes: an essential piece of the puzzle182
Beyond the modular brain178
Elia M Pestana Knight162
Delving into the human mind161
Albert Kwaku Akpalu159
A blood test for Alzheimer's disease: a step forward157
Considering the neurological health needs of LGBTQIA people154
Safe laboratory management of prions and proteopathic seeds152
Diana Cejas151
Gene therapy for X-linked myotubular myopathy: the challenges148
The prescription of valproate: risk of harm147
Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm tri146
Correction to Lancet Neurol 2022; 21: 284–94143
Correction to Lancet Neurol 2023; 22: 812–25143
Amyotrophic lateral sclerosis from genotoxins alone?141
A nasal CGRP receptor antagonist for acute migraine therapy139
Surrogate endpoints for progressive multifocal leukoencephalopathy135
Parkinson's disease is a recognisable and useful diagnostic entity130
Development of treatments for Down syndrome124
Aspiring to restore arm and hand function after stroke123
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial122
A sensitive portrayal of a controversial condition119
The Genetic Epidemiology of Parkinson's Disease view – Authors' reply117
From stroke awareness to stroke action awareness117
Complex regional pain syndrome: advances in epidemiology, pathophysiology, diagnosis, and treatment116
Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial116
Movement disorders research in 2021: cracking the paradigm114
Fluid balance and outcome in critically ill patients with traumatic brain injury (CENTER-TBI and OzENTER-TBI): a prospective, multicentre, comparative effectiveness study112
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases106
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised contro104
Encephalitis awareness: our ambitious global endeavour103
Better buildings for elderly people to thrive101
New results for risdiplam in spinal muscular atrophy100
Expansion of stenting indications in the USA100
Correction to Lancet Neurol 2021; 20: 687–8997
Jessica Ailani97
Neurological infections in 2023: surveillance and prevention97
Responsible innovation in neurology96
The International Brain Initiative: enabling collaborative science95
Multiple sclerosis in 2022: old players, new insights94
Brain health in the Philippines94
Correction to Lancet Neurol 2024; 23: 110–2292
Correction to Lancet Neurol 2022; 21: 620–3192
Detection of ionising radiation by the CNS: a case report89
Redefining use of MRI for patients with multiple sclerosis88
Cognitive function in people with functional seizures88
The ATTeST trial in ataxia telangiectasia: some concerns – Authors' response87
A health literacy campaign for Parkinson's disease in Africa: a novel campaign to break down language barriers87
Changing multiple-sclerosis-induced thoughts and behaviours86
Supporting young carers across neurological disorders85
Learning to be an adult with a disability84
Major advances in Parkinson's disease over the past two decades and future research directions83
0.032029151916504